Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
Programa de Pós-Graduação em Biologia Parasitária, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Med Mycol. 2022 Jun 30;60(6). doi: 10.1093/mmy/myac033.
There is an urgent need to develop novel antifungals. In this study, we screened 1600 compounds for antifungal activity against Cryptococcus neoformans and Candida auris. We evaluated 4 promising compounds against 24 additional isolates of Cr. neoformans, Ca. auris, Cr. deuterogattii, and Cr. gattii. The four compounds, dequalinium chloride (DQC), bleomycin sulfate (BMS), pentamidine isethionate salt (PIS), and clioquinol (CLQ), varied in their efficacy against these pathogens but were generally more effective against cryptococci. The compounds exerted their antifungal effect via multiple mechanisms, including interference with the capsule of cryptococci and induction of hyphal-like morphology in Ca. auris. Our results indicate that DQC, BMS, PIS, and CLQ represent potential prototypes for the future development of antifungals.
Fungal infections can be lethal and the options to fight them are scarce. We tested 1600 molecules for their ability to control the growth of two important fungal pathogens, namely Candida auris and species of Cryptococcus. Four of these compounds showed promising antifungal activities.
迫切需要开发新型抗真菌药物。在这项研究中,我们筛选了 1600 种化合物,以评估它们对新型隐球菌和耳念珠菌的抗真菌活性。我们评估了 4 种有前途的化合物对 24 种新型隐球菌、耳念珠菌、近平滑念珠菌和格特隐球菌的额外分离株的抗真菌活性。这四种化合物,盐酸地喹氯铵(DQC)、博来霉素硫酸盐(BMS)、戊烷脒(PIS)和氯喹(CLQ),对这些病原体的疗效不同,但通常对隐球菌更有效。这些化合物通过多种机制发挥其抗真菌作用,包括干扰隐球菌的荚膜和诱导耳念珠菌菌丝样形态。我们的结果表明,DQC、BMS、PIS 和 CLQ 代表了未来抗真菌药物开发的潜在原型。
真菌感染可能是致命的,而可用的治疗方法却很少。我们测试了 1600 种分子,以评估它们控制两种重要真菌病原体(即耳念珠菌和新型隐球菌)生长的能力。其中四种化合物显示出有希望的抗真菌活性。